Ozempic vs. Wegovy: What's Actually Different?

Ozempic and Wegovy are the same drug. Both contain semaglutide — the same active molecule, manufactured by the same company (Novo Nordisk), injected the same way (once weekly, subcutaneously). If you've wondered why two different products seem to do the same thing, you're asking exactly the right question.

The differences are real, but they live in FDA-approved indications, maximum doses, insurance coverage pathways, and price. Understanding those distinctions is practically important — it can mean the difference between a medication costing $25/month or $1,200/month.

The Shared Foundation: Semaglutide

Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a hormone naturally released after eating that:

• Stimulates insulin secretion (glucose-dependent)
• Suppresses glucagon (reducing liver glucose output)
• Slows gastric emptying
• Acts on the hypothalamus and brainstem to reduce appetite and food intake

Originally developed for type 2 diabetes, Novo Nordisk's clinical programs demonstrated that higher doses produced meaningful weight loss in people without diabetes — leading to the separate product development, branding, and FDA approval of Wegovy.

Both drugs have the same molecular structure. Both are administered via subcutaneous injection. Both start at 0.25 mg/week and escalate.

FDA Approval: The Critical Difference

	Ozempic	Wegovy
FDA Approved For	Type 2 diabetes; cardiovascular risk reduction in T2D patients with established CVD	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related condition
Approval Year	2017	2021
Maintenance Dose	0.5 mg, 1.0 mg, or 2.0 mg weekly	2.4 mg weekly
Pen Doses Available	0.25 mg, 0.5 mg, 1 mg, 2 mg	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg

The FDA approval for Wegovy in June 2021 was based on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, which used the 2.4 mg dose. The FDA approval for Ozempic for diabetes was based on the SUSTAIN trial program.

The highest approved dose of Ozempic is 2.0 mg — and that dose was added later, in 2022. Wegovy's maintenance dose of 2.4 mg is the highest approved semaglutide dose and is what drove the landmark weight loss results in STEP 1.

Weight Loss Results by Dose

Dose matters. A lot. Here's what the clinical data shows:

• Ozempic 1.0 mg (typical diabetes dose): ~4–6 kg weight loss in SUSTAIN trials
• Ozempic 2.0 mg: ~6–8 kg in SUSTAIN 7
• Wegovy 2.4 mg: ~15.3 kg (33.7 lbs) average weight loss over 68 weeks in STEP 1

This isn't a small difference. The dose matters enormously, and Wegovy's 2.4 mg approval was specifically designed to maximize weight loss outcomes. Using Ozempic at its diabetes-indicated doses for weight management produces meaningfully less weight loss on average.

Off-Label Use of Ozempic for Weight Loss

Because Ozempic is the same molecule as Wegovy, some providers prescribe it off-label for weight management in patients without diabetes. This is legal and relatively common — particularly when:

• Wegovy is out of stock (which has been a periodic issue since its 2021 launch)
• The patient's insurance covers Ozempic but not Wegovy
• The prescriber has a clinical reason to use a lower maintenance dose

However, off-label Ozempic for weight loss creates several issues:

1. Insurance won't cover it as a weight loss drug. Most commercial insurers specifically exclude off-label prescribing. You may pay out-of-pocket.
2. The maximum dose pen for Ozempic (2 mg) still doesn't reach Wegovy's 2.4 mg maintenance dose.
3. Novo Nordisk's savings cards are specific to indication. The Ozempic savings card is for diabetes; the Wegovy savings card is for obesity.

Insurance Coverage

This is where the practical rubber meets the road.

Ozempic (diabetes): - Widely covered by commercial insurance for T2D patients — it has been on formulary at major payers for years - Medicare Part D covers Ozempic for diabetes - Novo Nordisk offers a savings card reducing cost to as low as $25/month for eligible commercially insured patients

Wegovy (obesity): - Coverage has historically been inconsistent. The Treat and Reduce Obesity Act was intended to expand Medicare coverage to obesity drugs, but as of 2026 coverage remains variable. - Some commercial employers and large insurers cover Wegovy; others exclude obesity medications by category - Novo Nordisk's Wegovy savings program may reduce out-of-pocket cost to $0/month for eligible commercially insured patients who qualify - Without insurance: List price approximately $1,349/month (see our cost estimator for current pricing and savings options)

The American Obesity Association's ObesityActionCoalition maintains updated insurance coverage guidance and appeals resources.

Side Effect Profiles: Essentially the Same

Because it's the same molecule, the side effect profiles of Ozempic and Wegovy are effectively identical — nausea, vomiting, diarrhea, constipation, burping — just potentially more pronounced at Wegovy's higher 2.4 mg dose. The titration schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16–20 weeks) is designed specifically to minimize side effects at each escalation.

Both carry the same FDA boxed warning regarding thyroid C-cell tumors (observed in rodent studies; clinical relevance in humans remains under investigation) and the same contraindication for patients with personal or family history of medullary thyroid carcinoma or MEN 2.

The Cardiovascular Angle

In 2024, the SELECT trial reported that semaglutide 2.4 mg (the Wegovy dose) reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease, overweight or obesity, but without diabetes. This was a landmark finding — the first cardiovascular outcome trial for a GLP-1 medication in a predominantly non-diabetic population.

As a result, the FDA approved a new indication for Wegovy in March 2024: reducing cardiovascular risk in adults with obesity or overweight with established CVD. This may shift insurance coverage dynamics significantly, as cardiovascular indications have broader payer acceptance than obesity alone.

Ozempic, used at diabetes doses (0.5–2 mg), also demonstrated cardiovascular benefit in the SUSTAIN-6 trial, but those results were in type 2 diabetes patients.

Practical Decision Guide

Choose Wegovy if: - Your primary goal is weight management - You have BMI ≥30, or ≥27 with a weight-related condition (hypertension, sleep apnea, etc.) - Your insurance covers Wegovy - You want access to the full 2.4 mg dose and the maximum supported weight loss

Ozempic may be the right choice if: - You have type 2 diabetes (it's the approved indication) - Your insurance covers Ozempic but not Wegovy - Your provider determines a lower maintenance dose is appropriate - Supply issues affect Wegovy availability in your area

Discuss with your prescriber either way. The choice isn't purely clinical — it involves insurance, cost, access, and your specific metabolic situation.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. FDA. "Wegovy (semaglutide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
3. FDA. "Ozempic (semaglutide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
4. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
5. FDA News Release. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." March 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
6. Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)." NEJM, 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141